Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lefamulin versus moxifloxacin in adults with community-acquired bacterial pneumonia
2014-005169-63Phase 3Completed
- Sponsor
- Nabriva Therapeutics plc
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lefamulin in community acquired pneumonia (CAP) and bacterial pneumonia (2 arms), sponsored by Nabriva Therapeutics plc. Primary endpoint: Early Clinical Response in ITT analysis set. Started Oct 2015; status: completed.
02
Drugs
lefamulin
03
Conditions
community acquired pneumonia (CAP)bacterial pneumonia
Beyond the preview
Go deeper on 2014-005169-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005169-63.